<ul data-eligibleForWebStory="false"><li>San Diego startup Gallant has secured $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for veterinary medicine.</li><li>The therapy aims to address conditions in pets like Feline Chronic Gingivostomatitis (FCGS) and arthritis, with promising early results showing improvements in pain and mobility.</li><li>Gallant's approach differentiates itself by utilizing ready-to-use cells from donor animals, potentially simplifying the treatment process compared to traditional stem cell therapies.</li><li>Investors, including Digitalis Ventures and NovaQuest Capital Management, are optimistic about Gallant's potential, recognizing its novel approach and convenience.</li></ul>

Ready-made stem cell therapies for pets could be coming

Discover more